Page last updated: 2024-09-03

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and Left Ventricular Hypertrophy

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with Left Ventricular Hypertrophy in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calderone, A; Clement, R; Colombo, F; Gosselin, H; Mercier, I; Pham-Dang, M; Rouleau, JL1

Other Studies

1 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and Left Ventricular Hypertrophy

ArticleYear
Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis.
    British journal of pharmacology, 2002, Volume: 136, Issue:5

    Topics: Animals; Blood Pressure; Dansyl Compounds; Endomyocardial Fibrosis; Endothelin Receptor Antagonists; Female; Hypertension; Hypertrophy, Left Ventricular; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Endothelin

2002